Business
NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023
NewAmsterdam to review data on webcast conference call on June 5, 2023 at 8:00 a.m. ET NAARDEN, the Netherlands and MIAMI, May 23, 2023 (GLOBE NEWSWIRE) --
About this update from Newamsterdam Pharma Company N.v.
[{"type":"text","content":"NewAmsterdam to review data on webcast conference call on June 5, 2023 at 8:00 a.m. ET\nNAARDEN, the Netherlands and MIAMI, May 23, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, today announced that it will present full data from ROSE2, a Phase 2 clinical trial evaluating obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy, in a late-breaking presentation at the National Lipid Association (“NLA”) Scientific Sessions, being held June 1-4 in Atlanta, Georgia. NewAmsterdam is developing a fixed dose combination of obicetrapib 10 mg and ezetimibe 10 mg, and expects to select a formulation to advance into a definitive bioequivalence trial and a Phase 3 safety and efficacy trial in the second half of 2023. Details of the presentation are as follows: Presentation Title: The combination of Obicetrapib and Ezetimibe lowers LDL-C in Patients on High Intensity Statins: Results from the ROSE2 Trial (NCT05266586)Session Title: Late-Breaker SessionSession Date and Time: Saturday, June 3, 2023, 12:00 P.M. ETLocation: Omni Atlanta Hotel at CNN Center Investor and Analyst Conference Call and Live Webcast NewAmsterdam will host a conference call for investors and analysts to review the full data from ROSE2. The live webcast will begin at 8:00 a.m. ET on Monday, June 5 and will include remarks by Robert Rosenson, M.D., a Professor of Medicine, and Director of Cardiometabolic Disorders at the Icahn School of Medicine at Mount Sinai. Participants may register for the conference call here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. A live webcast of the call will also be available under “Events & Presentations” in the Investors & News section of the Company’s website at https://ir.newamsterdampharma.com. The archived webcast will be available on NewAmsterdam’s website approximately two hours after the conference call and will be available for at least 30 days following the live event. About NewAmsterdam NewAmsterdam (Nasdaq: NAMS) is a clinical-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic d...